Relative efficacy of each treatment vs placebo in the mixed-treatment metaanalysis.
| Treatment | ACR20 OR (95% CrI) | ACR50 OR (95% CrI) | ACR70 OR (95% CrI) |
|---|---|---|---|
| Random-effects Model | |||
| Infliximab | 3.31 (2.05–5.03) | 3.59 (1.97–6.13) | 3.55 (1.77–7.15) |
| Etanercept | 8.07 (3.34–16.75) | 11.45 (3.45–31.02) | —* |
| Adalimumab | 3.72 (2.35–5.93) | 5.66 (3.15–10.01) | 6.63 (3.12–12.69) |
| Golimumab | 3.62 (1.62–6.97) | 5.72 (2.07–13.69) | —* |
| Certolizumab pegol | 11.82 (5.98–21.71) | 10.81 (4.41–24.02) | 15.84 (4.64–43.89) |
| Anakinra | 2.40 (0.96–5.03) | 2.84 (0.81–7.26) | —* |
| Tocilizumab | 4.13 (2.64–6.19) | 5.68 (2.78–9.93) | 8.63 (3.70–16.99) |
| Fixed-effects Model | |||
| Infliximab | 3.36 (2.65–4.20) | 3.51 (2.62–4.63) | 3.18 (2.12–4.63) |
| Etanercept | 7.79 (4.07–13.86) | 9.76 (4.09–21.19) | —* |
| Adalimumab | 3.12 (2.46–3.89) | 4.87 (3.58–6.54) | 6.26 (3.89–9.74) |
| Golimumab | 3.61 (2.14–5.76) | 4.77 (2.52–8.38) | —* |
| Certolizumab pegol | 10.94 (7.42–15.81) | 9.43 (5.60–15.43) | 12.83 (5.61–28.08) |
| Anakinra | 2.24 (1.49–3.26) | 2.53 (1.39–4.32) | —* |
| Tocilizumab | 4.09 (3.43–4.86) | 5.92 (4.47–7.79) | 8.48 (5.37–13.06) |
↵* Insufficient numbers of patients. ACR: American College of Rheumatology. CrI: credible interval.